The Efficacy and Safety of Imipenem/Cilastatin in the Treatment of Severe Bacterial Infections

Summary

We have assessed the efficacy and safety of imipenem/cilastatin in a non-comparative study of 27 immunocompromised patients suffering from severe bacterial infections. Moreover, in two groups of 14 patients the efficacy of imipenem/cilastatin versus a standard broad spectrum antibiotic therapy has also been compared. Clinical and microbiological efficacy and side effects have been evaluated.

Key Words:

• imipenem/cilastatin
• immunocompromised host
• severe bacterial infections
• side effects